- Home
- Applications
- usa california
- therapy discogenic cell
Refine by
Therapy Discogenic Cell Product Applications Available In Usa California
18 applications found
Degenerative disc disease is a chronic and progressive condition that is characterized by inflammation and breakdown of tissue within the intervertebral disc. Located between the vertebral bones in the spine, the intervertebral disc acts like a pillow to cushion and evenly distribute pressure across the vertebrae. Each disc is comprised of an outer fibrous ring, the annulus fibrosus, which surrounds an inner gel-like center, the nucleus pulposus. ...
ByDiscGenics, Inc. based in Salt Lake City, UTAH (USA)
Absence of a means for affordable and effective cell engineering hinders the commercialization of these advanced treatments. CellFE’s technology can get life-saving therapies to the patient at lower cost, with shorter manufacturing time, and higher retention of inherent ...
ByCellFE based in San Carlos, CALIFORNIA (USA)
Premium
Novel cell therapies show great promise as treatments for a variety of complex diseases including cancers and neurodegenerative disorders. Flow imaging microscopy supports drug product analysis in order to advance the development of these therapies. ...
ByYokogawa Fluid Imaging Technologies, Inc. based in Scarborough, MAINE (USA)
The first product candidate to utilize the Discogenic Cell platform is IDCT ...
ByDiscGenics, Inc. based in Salt Lake City, UTAH (USA)
A critical question in determining the mechanism of action of cell therapies is “do the cells go where you want them to?” Clinical cell tracking can answer this question and CellFE technology is uniquely suited for delivering of FDA-approved contrast agents to ...
ByCellFE based in San Carlos, CALIFORNIA (USA)
Solid tumor-specific Affilin molecules are currently being evaluated as CAR-T ligands. Specifically, they were confirmed to be functionally expressed on the effector cell surface, mediate target cell-binding and effective target cell-killing in a dose-dependent fashion. Importantly they were just as effective as commonly used antibody ...
ByNavigo Proteins GmbH based in Halle, GERMANY
For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in ...
ByEli Lilly and Company based in Indianapolis, INDIANA (USA)
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...
ByKiadis Pharma NV based in Amsterdam, NETHERLANDS
In cell therapy, the source and quality of albumin has proven important for both performance and regulatory purposes. Albumedix' recombinant human albumin products are used in a range of cell therapy media and products offering increased viability, consistency and ...
BySartorius AG based in Goettingen, GERMANY
The manufacture of biopharmaceutical agents such as therapeutic monoclonal antibodies, vaccines and cell-based therapies like CAR-T cells require the highest quality control against the contamination of adventitious agents. These pathogens can enter the manufacturing process at multiple stages and impact yield and safety. Current methods for detection of adventitious agents are expensive, lack sensitivity and have long turn around times to results. Moreover, many of the current adventitious agent testing methods ...
ByAccuGenomics, Inc. based in Wilmington, NORTH CAROLINA (USA)
Maximize the probability of your clinical trial success by accelerating patient enrollment and flexible operations. Whether it is investigator-initiated study, observational study, phase 0, 1, 2, 3, or 4 post-market trials, real-world evidence generation to supplement your randomized controlled clinical trial, maximizing the speed of patient enrollment is the proven way to minimize your ...
ByJeeva Informatics Solutions Inc. based in Manassas, VIRGINIA (USA)
Save 70% of your time and maximize the probability of success of your clinical study. Avoid common pitfalls by starting your cohort study, patient registry, observational data collection, or clinical trial on Jeeva eClinical cloud platform. Save over 70% of the effort involved in toggling between numerous tools, coordination between multiple channels of engagement between study team and participants, participants use their own mobile device, and study specific data governance. ...
ByJeeva Informatics Solutions Inc. based in Manassas, VIRGINIA (USA)
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
CROs can differentiate their services to sponsors with the white-labeled Jeeva eClinical technology platform advantage. Maximize the probability of winning contracts with sponsors by differentiating your proposals with Jeeva eClinical cloud. Sponsors want to know how you can ensure faster patient recruitment and better retention compared to your peers. Jeeva can rapidly turnaround with a budget proposal and branded material for inclusion in your response to sponsor RFPs and support you throughout the ...
ByJeeva Informatics Solutions Inc. based in Manassas, VIRGINIA (USA)
Real-time and label-free characterization of drug candidates in living ...
Bylino Biotech AG based in Zurich, SWITZERLAND
Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...
ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS
Simple and robust determination of critical quality attributes in ...
Bylino Biotech AG based in Zurich, SWITZERLAND
Laser Force Cytology (LFC) and Radiance label-free approach to cell therapy research and biomanufacturing has significant value in expediting the process, decreasing costs, and ensuring therapy effectiveness and quality. Radiance enhances the highly complex biomanufacturing process for cell therapies by providing new insights to cell therapy research and process development. Current process development assays are fraught with difficult and time-consuming steps requiring highly skilled scientists and bioengineers ...
ByLumaCyte, Inc. based in Charlottesville, VIRGINIA (USA)